Skip to main content
Home
  • Get Care
    • Find a Doctor
    • Request an Appointment
    • Virtual Visits
    • Locations & Directions
    • News
    • About Columbia Surgery
    • All Resources
  • Surgical Specialties
      • Adrenal
      • Aorta
      • Breast
      • Colorectal
      • Colorectal (Global Center)
      • Esophageal
      • Gall Bladder & Appendix
      • Gastric Cancer
      • Heart (Adult)
      • Heart (Pediatric)
      • Hernia
      • Kidney/Pancreas Transplantation
      • Liver Transplantation
      • Lung & Chest
      • Melanoma
      • Pancreas
      • Parathyroid
      • Pediatric/Neonatal
      • Plastic & Reconstructive
      • Robotic Surgery
      • Sarcoma
      • Thyroid
      • Vascular
      • Weight Loss Surgery
    • All Specialties
  • Research & Trials
    • About Research
    • About Clinical Trials
    • Basic & Translational Research
    • Cardiovascular Research
    • Clinical Research
    • Innovation & Outcomes Research
    • Translational Immunology Research
    • Transplant Research
    • All Research & Trials
  • Conditions & Treatments
      • Adrenal
      • Aortic
      • Breast
      • Colorectal
      • Esophageal
      • Gallbladder & Appendix (General Surgery)
      • Heart (Adult)
      • Hernia
      • Kidney
      • Liver
      • Lung & Chest (Thoracic)
      • Pancreas
      • Parathyroid
      • Pediatric (Neonatal)
      • Plastics (Cosmetic & Reconstructive)
      • Skin
      • Stomach (Gastric)
      • Thyroid
      • Vascular
      • Weight Loss (Bariatric)
    • All Conditions and Treatments
  • For Students and Professionals
  • Ways to Help
  • Request an Appointment

Search results

A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination with Sofosbuvir for the Treatment of Post-Liver Transplant Subjects with Chronic Hepatitis C

… of this program is to provide DCV for 24 weeks to be given in combination with SOF to subjects with chronic hepatitis C … Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination with Sofosbuvir for the Treatment of …

Last Modified: 02/13/2023 - 21:06

A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma

… to receiving dabrafenib and trametinib with a break in treatment. Dabrafenib and trametinib are similar to … whether receiving dabrafenib and trametinib with a break in treatment could extend the time before your cancer gets … study will allow the researchers to know whether a break in treatment is better, the same, or worse than continuous …

Last Modified: 02/13/2023 - 21:06

A Phase III Randomized, Controlled, Superiority Study Evaluating EVARREST Fibrin Sealant Patch Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Hepatic Surgery

… Patch (EVARREST) versus standard of care treatment (SoC) in controlling parenchymal bleeding during hepatic surgery. … Fibrin Sealant Patch Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Hepatic Surgery …

Last Modified: 02/13/2023 - 21:06

A Phase II Randomized Multicenter Placebo- Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients with Hepatocellular Carcinoma (HCC)

… and effective treatment option for preventing liver cancer in high risk patients following liver transplantation. Liver … but despite transplantation, the liver cancer can recur in the new, transplanted liver. It is not known whether sorafenib is effective in preventing cancer recurrence in high risk patients …

Last Modified: 02/13/2023 - 21:06

A Phase II Study of Chemotherapy and Immune Checkpoint Blockade With Pembrolizumab in the Perioperative and Maintenance Treatment of Locoregional Gastric or GE Junction Adenocarcinoma

… with immune checkpoint blockade and chemotherapy used in the perioperative period in eradicating micrometastatic disease. Additionally, the … and Immune Checkpoint Blockade With Pembrolizumab in the Perioperative and Maintenance Treatment of …

Last Modified: 02/13/2023 - 21:07

A single center, open-label, randomized, controlled pilot trial to evaluate the efficacy and safety of everolimus conversion versus standard immunosuppression in liver transplant recipients

… compared to the standard tacrolimus (TAC) based protocol in liver transplant recipients, as determined by renal … function, rejection rates, and progression to fibrosis (in HCV positive subjects). Additionally, safety profile and … of everolimus conversion versus standard immunosuppression in liver transplant recipients …

Last Modified: 02/13/2023 - 21:06

Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052) (C-SURFER)

… Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection and … and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney …

Last Modified: 02/13/2023 - 21:06

Looking for patient to enroll in Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas

… is the third-most common cause of cancer-related death in the US. In some cases, surgical removal of the pancreas is considered … cancer cells both at the operative stage and once removed. In this new study, the Pancreas Center has partnered with a … Looking for patient to enroll in Preoperative Extended Chemotherapy vs. Chemotherapy Plus …

Last Modified: 01/13/2025 - 12:06

Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone In Patients With Incurable Lung or Non- Colorectal Gastrointestinal Malignancies

… reported quality of life at 12 weeks using the FACT in patients with newly diagnosed incurable lung or … Standard Oncology Care Versus Standard Oncology Care Alone In Patients With Incurable Lung or Non- Colorectal …

Last Modified: 02/13/2023 - 21:07

Prospective, non-randomized, open label clinical study to assess the feasibility of the Bioabsorbable pulmonary valved conduit in subjects undergoing Right Ventricular Outflow Tract (RVOT) reconstruction

… of the Xeltis Bioabsorbable Pulmonary Valved Conduit in subjects requiring Right Ventricular Outflow Tract … feasibility of the Bioabsorbable pulmonary valved conduit in subjects undergoing Right Ventricular Outflow Tract (RVOT) …

Last Modified: 02/13/2023 - 21:07

Expanded-access single named patient guidance document for the use of BMS 790052 in combination with sofosbuvir for the treatment of a patient with recurrent hepatitis C virus infection

… named patient guidance document for the use of BMS 790052 in combination with sofosbuvir for the treatment of a patient …

Last Modified: 02/13/2023 - 21:06

A Phase 2 open-label study in patients with recurrent Genotype 1 hepAtitis C post orthotopic Liver transplAnt to eXplore the safety and efficacY of simeprevir and sofosbuvir with and without ribavirin

… and 24 weeks of simeprevir plus sofosbuvir without RBV in post orthotopic liver transplant participants with … A Phase 2 open-label study in patients with recurrent Genotype 1 hepAtitis C post …

Last Modified: 02/13/2023 - 21:06

A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir, in Orthotopic Liver Transplant Recipients

… Hepatitis C Immune Globulin Intravenous (Human), Civacir, in Orthotopic Liver Transplant Recipients …

Last Modified: 02/13/2023 - 21:06

A 24 month, randomized, controlled, study to evaluate the efficacy and safety of concentration-controlled everolimus plus reduced tacrolimus compared to standard tacrolimus in recipients of living donor liver transplants

… is to demonstrate the efficacy and safety of everolimus in combination with reduced tacrolimus, compared to tacrolimus control, in living donor liver transplant recipients. Trial Website: … plus reduced tacrolimus compared to standard tacrolimus in recipients of living donor liver transplants …

Last Modified: 02/13/2023 - 21:06

A Phase 3b study to evaluate the long-term outcomes following treatment with Abbvie DAAs and with or without Ribavirin (RBV) in adults with genotype 1 Chronic Hepatitis C Virus (HCV) Infection

… with ABT-450/r/ABT-267, ABT-333 with or without RBV in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) … with Abbvie DAAs and with or without Ribavirin (RBV) in adults with genotype 1 Chronic Hepatitis C Virus (HCV) …

Last Modified: 02/13/2023 - 21:06

Pagination

  • « First First page
  • ‹‹ Previous page
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • ›› Next page
  • Last » Last page

Footer About

  • About Us
  • Request an Appointment
  • Virtual Visits
  • Organ Donation
  • Contact Us
  • Subscribe To Our Newsletter

Footer About 2

  • Directory
  • Alumni/JJSS
  • Locations & Directions
  • Ways to Help
  • Disclaimer
FOLLOW US
  • Twitter Logo
  • Facebook Logo
  • Youtube Logo
  • Instagram Logo
Visit
  • New York Presbyterian Logo
  • Columbia University Irving Medical Center Logo

©1999-2026. Columbia University Irving Medical Center, Department of Surgery, New York, NY.